MET体细胞激活突变导致淋巴静脉畸形,可通过cfDNA液体活检识别
本研究选取4例淋巴静脉畸形患者,从外周及畸形部位引流静脉血浆提取游离DNA,并行组织活检。结果显示4例均存在MET激活突变,其中3例为T1010I;有组织样本者组织水平亦检出该突变,提示cfDNA二代测序液体活检可无创识别MET突变。
要点
- 淋巴静脉畸形患者可检出MET体细胞激活突变,3/4例为T1010I。
- cfDNA二代测序液体活检可在外周及引流静脉血中识别MET突变。
- 液体活检无创、避免出血风险,便于儿童患者应用。
核心结论
- 淋巴静脉畸形可能由淋巴发育关键基因的体细胞激活突变所致,cfDNA液体活检可识别MET突变。
研究设计与样本
- 选取4例淋巴静脉畸形患者,采集外周及畸形部位引流静脉血浆提取cfDNA,并在可能时分析病变组织活检。
主要发现
- 4例患者均存在MET激活突变,其中3例为同一致病性激活突变T1010I。
- 有组织样本的1例在组织水平检出该突变,支持其在淋巴静脉畸形中的致病作用。
关键数值与推荐
- 4例淋巴静脉畸形患者中4例检出MET激活突变,3例为T1010I。
临床怎么用
- 对淋巴静脉畸形可考虑cfDNA二代测序液体活检识别MET突变,尤其适用于儿童等需避免出血风险者。
- 检出MET突变可能为后续针对基因缺陷的个体化治疗提供依据。
局限性
- 样本仅4例,需更大队列证实MET突变在淋巴静脉畸形中的致病作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Germline mutations of either the endothelial cell-specific tyrosine kinase receptor TIE2 or the glomulin (GLMN) gene are responsible for rare inherited venous malformations. Both genes affect the hepatocyte growth factor receptor c-Met, inducing vascular smooth muscle cell migration. Germline mutations of hepatocyte growth factor are responsible for lymphatic malformations, leading to lymphedema. The molecular alteration leading to the abnormal mixed vascular anomaly defined as lymphovenous malformation has remained unknown. METHODS: A group of 4 patients with lymphovenous malformations were selected. Plasma was obtained from both peripheral and efferent vein samples at the vascular malformation site for cell-free DNA extraction. When possible, we analyzed tissue biopsy samples from the vascular lesion. RESULTS: We have demonstrated that in all four patients, an activating MET mutation was present. In three of the four patients, the same pathogenic activating mutation, T1010I, was identified. The mutation was found at the tissue level for the patient with tissue samples available, confirming its causative role in the lymphovenous malformations. CONCLUSIONS: In the present study, we have demonstrated that cell-free DNA next generation sequencing liquid biopsy is able to identify the MET mutations in affected tissues. Although a wider cohort of patients is necessary to confirm its causative role in lymphovenous malformations, these data suggest that lymphovenous malformations could result from postzygotic somatic mutations in genes that are key regulators of lymphatic development. The noninvasiveness of the method avoids any risk of bleeding and can be easily performed in children. We are confident that the present pioneering results have provided a viable alternative in the future for lymphovenous malformation diagnosis, allowing for subsequent therapy tailored to the genetic defect.
引用
- Palmieri M, Di Sarno L, Tommasi A, et al. MET somatic activating mutations are responsible for lymphovenous malformation and can be identified using cell-free DNA next generation sequencing liquid biopsy. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32858245. doi:10.1016/j.jvsv.2020.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。